

JAGSONPAL PHARMACEUTICALS LIMITED

CIN: L74899DL1978PLC009181

Registered Office: T-210 J, Shahpur Jat, New Delhi – 110049 Phone: 011-46181100 & 46109900, FAX: 011-26498341

Website: <u>www.jagsonpal.com</u> , E-mail: <u>nandita.singh@jagsonpal.com</u>

Date: April 28 th , 2021	
The Manager	The Manager
Listing Agreement	Listing Agreement
The National Stock Exchange of India Ltd.	The BSE Limited
Exchange Plaza,	Pherojbhoy Jeejeebhoy Tower
Bandra-Kurla Complex	Dalal Street,
Bandra (E), Mumbai - 400 051.	Mumbai - 400 001.
CM Quote : JAGSNPHARM	SCRIP Code : 507789
Subject: Submission of Certificate under Sub- Regulation 9 & 10 Regulation 40 of the SEBI (Listing Obligations & Disclosure Requirement) Regulations, 2015 for the half	

Dear Sir & Madam,

Pursuant to the provisions of Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations' "), please find enclosed herewith the Certificate dated April 28, 2021 for the half year ended March 31st, 2021. This certificate has been issued by Mr. Mukesh Arora proprietor of M/s Mukesh Arora & Co.

You are requested to take the above information on record.

You are requested to do the needful. For JAGSONPAL PHARMACEUTICALS LIMITED

Nandita Singh Company Secretary & Compliance Officer Membership No.: A48520

Mukesh Arora & Company

Company Secretaries


CERTIFICATE UNDER REGULATION 40(9) OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

FOR THE HALF YEAR ENDED ON 31st MARCH, 2021.

I have examined all share transfer deeds, memorandum of transfers, sub-division, consolidation, renewal, exchange or endorsement of calls/ allotment monies, registers, files and other documents relating to JAGSON PAL PHARMACEUTICALS LIMITED maintained by MCS SHARE TRANSFER AGENET LIMITED pertaining to transfer of equity shares of the company for the period from 1ST October, 2020 to 31st March, 2021 for the purpose of issuing a certificate as per regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 entered into by, JAGSON PAL PHARMACEUTICALS LIMITED with BSE LTD and NSE LTD and based on the information provided by the company, I hereby certify that the company has delivered during half year ended on 31st March, 2021:

Based on my examination of the aforesaid record and written certificate provided by Jagsonpal Pharmaceuticals Ltd, I hereby certify that there was no occasion to deliver any share certificate after transfer during half year ended on 31st March,2021 as no request for transfer of shares was received during the period from 1st October, 2020 to 31st March, 2021. Besides this there was no case of sub-division, duplicate, renewal, splitting, consolidation from respective date of lodgment of each deed within this period.

Place: New Delhi Date: 28.04.2021 UDIN: F004819C000201851



Chamber No. 304, 12/1117, Naiwala, Karol Bagh, New Delhi-110005 Ph.: 28754547, (M)9810015715